BALTIMORE--(BUSINESS WIRE)--An investigational flu vaccine based on a novel technology that could dramatically improve the potency, manufacturing capacity and cost effectiveness of flu vaccines, was safe and immunogenic in a Phase I trial presented at the National Foundation for Infectious Diseases’ (NFID) Twelfth Annual Conference on Vaccine Research here today.
